The next treatment-resistant depression paradigm
From BioSpace · · 20 min
This plays from the publisher's own server. We do not host a copy.
Description
In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass Pathways. We explore why treatment-resistant depression remains so difficult to address, and how new approaches—from rapid-acting antidepressants to psychedelic therapy—may reshape the treatment paradigm.
Host
Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace
Guests
Hans Eriksson, (https://www.linkedin.com/in/hansaeriksson/) Chief Medical Officer, FundaMental Pharma
Steve Levine (https://www.linkedin.com/in/steve-levine-md-43908a12/), Chief Patient Officer, Compass Pathways
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.